Menu
Recruiting NCT07375225

Evaluation of Adherence, Persistence and Efficacy of Treatment With Alirocumab 300mg in Italy

— Observational Hypercholesterolaemia

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Praluent (Alirocumab).
Who it may be relevant to
Registry conditions: Hypercholesterolaemia. Basic parameters: 18 years — 80 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Italy
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Evaluation of Adherence, Persistence and Efficacy of Treatment With Alirocumab 300mg in Italy - The ALINET Registry

Overview

Evaluation of adherence, persistence and efficacy of treatment with alirocumab 300 mg in a real-life Italian population.

Interventions

  • Drug Praluent (Alirocumab)
    Alirocumab 300 mg injection

Primary outcome measures

  • Description of adherence of treatment with alirocumab 300mg in a real-life Italian population. [Time frame: 6-12-24-36 months]
  • Description of persistence of treatment with alirocumab 300mg in a real-life Italian population. [Time frame: 6-12-24-36 months]
  • Description of efficacy of treatment with alirocumab 300mg in a real-life Italian population. [Time frame: 6-12-24-36 months]
Secondary outcome measures (1)
  • Description of safety of treatment with alirocumab 300mg in a real-life Italian population. [Time frame: 6-12-24-36 months]

Eligibility criteria

Inclusion criteria

\- Patients under alirocumab 300mg treatment.

Exclusion criteria

  • Age < 18 years o > 80 years;
  • Patients who refuse to participate and to sign informed consent.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Case-only

Study locations

Italy · 1 center
  • Federico II University of Naples, Department of Advanced Biomedical Sciences — Naples

Identifiers

NCT: NCT07375225 · Prot. 28/2024

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗